Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsPeripheral Blood Stem Cell TransplantationBone MarrowTransplantation, HomologousBone Marrow TransplantationMelphalanMultiple MyelomaCombined Modality TherapyTransplantation ConditioningTreatment OutcomeRemission InductionBone Marrow CellsCytarabineCyclophosphamideEtoposideDisease-Free SurvivalSalvage TherapyStem CellsLymphoma, Non-HodgkinRecurrenceHodgkin DiseaseSurvival RateVincristineSurvival AnalysisCarmustineBone Marrow PurgingMyeloablative AgonistsGraft vs Host DiseaseDoxorubicinThiotepaHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHematologic NeoplasmsWhole-Body IrradiationPrognosisAntineoplastic AgentsBusulfanRetrospective StudiesLeukemia, Myeloid, AcuteFollow-Up StudiesLymphoma, Mantle-CellDexamethasoneAntigens, CD34IfosfamideAmyloidosisBone and BonesTime FactorsGraft SurvivalGranulocyte Colony-Stimulating FactorBoronic AcidsAntineoplastic Agents, AlkylatingChemotherapy, AdjuvantPyrazinesAntibodies, Monoclonal, Murine-DerivedLymphomaPrednisoneLymphoma, FollicularLymphoma, T-Cell, PeripheralIdarubicinInduction ChemotherapyMyelodysplastic SyndromesNeoplasm, ResidualAutograftsThalidomideLiver TransplantationMesenchymal Stem Cell TransplantationCisplatinLeukemia, MyeloidLymphoma, Large B-Cell, DiffuseMitoxantroneTransplantation ChimeraLeukapheresisPrecursor Cell Lymphoblastic Leukemia-LymphomaPodophyllotoxinProspective StudiesTissue DonorsDrug Administration ScheduleMaintenance ChemotherapyNeutropeniaLeukemiaHematopoiesisIntensive Care UnitsCell DifferentiationCord Blood Stem Cell TransplantationNeoplasm Recurrence, LocalCell TransplantationCarboplatinLymphoma, B-CellAcute DiseaseMethotrexateAntibodies, MonoclonalNeoplasm StagingBone Marrow DiseasesFeasibility StudiesNeoplasms, Second PrimaryKidney TransplantationEmbryonic Stem Cells